Table 2.
Residual symptoms, SGRQ score, lung function, and imaging findings on follow-up, by initial disease severity
| N (%) or Mean ± SD | p Value | ||||
|---|---|---|---|---|---|
| Total (n = 208) |
Mild (n = 86) |
Moderate (n = 49) |
Severe (n = 73) |
||
| Follow-up, days | 81 ± 50 | 85 ± 55 | 80 ± 48 | 74 ± 45 | 0.48 |
| Residual symptoms | |||||
| Asymptomatic | 12 (5.8) | 3 (3) | 7 (14.2) | 2 (2) | 0.52 |
| Pulmonary | 40 (9.2) | 13 (15.7) | 9 (21.4) | 18 (25.4) | |
| Extrapulmonary | 116 (55.8) | 20 (24.1) | 9 (21.4) | 11 (15.5) | |
| Both | 120 (57.7) | 50 (60.2) | 24 (57.1) | 42 (59.2) | |
| Dyspnea | 120 (57.7) | 42 (48.8) | 28 (57.1) | 50 (68.5) | 0.04 |
| Cough | 47 (22.6) | 17 (19.8) | 16 (32.7) | 14 (19.2) | 0.16 |
| Exercise intolerance | 50 (24) | 18 (20.9) | 13 (26.5) | 19 (26.0) | 0.68 |
| Chest pain | 34 (16.3) | 14 (16.3) | 7 (14.3) | 13 (17.8) | 0.87 |
| Fatigue | 126 (60.6) | 53 (61.6) | 24 (49.0) | 49 (67.1) | 0.13 |
| Arthralgia/myalgia | 45 (21.6) | 22 (25.6) | 7 (14.3) | 16 (21.9) | 0.31 |
| Hair Loss | 28 (13.5) | 15 (17.4) | 6 (12.2) | 7 (9.6) | 0.34 |
| Anxiety | 20 (9.6) | 11 (12.8) | 4 (8.2) | 5 (6.8) | 0.41 |
| Cognitive dysfunction | 59 (28.4) | 28 (32.6) | 12 (24.5) | 19 (26.0) | 0.52 |
| Anosmia/ageusia | 16 (7.7) | 10 (11.6) | 3 (6) | 3 (4) | 0.18 |
| SGRQ score | 39.6 ± 25.6 | 37 ± 24.8 | 42.8 ± 25.6 | 40.9 ± 26.7 | 0.67 |
| SaO2 | |||||
| Rest | 96.2 ± 2.05 | 96.8 ± 1.5 | 96.4 ± 1.5 | 95.3 ± 2.5 | < 0.001 |
| Exercise | 95.0 ± 3.0 | 96.2 ± 1.7 | 95.8 ± 1.7 | 93.3 ± 4.0 | < 0.001 |
| Spirometry | |||||
| FEV1, % predicted | 91.1 ± 17.8 | 94.7 ± 16.2 | 94.3 ± 15 | 85.2 ± 19.7 | < 0.001 |
| FVC, % predicted | 89.0 ± 18.3 | 94.9 ± 14.8 | 91.44 ± 14.7 | 81.3 ± 20.8 | < 0.001 |
| FEV1/FVC, % predicted | 82 ± 18.3 | 81 ± 11 | 83 ± 8 | 82 ± 10 | 0.87 |
| Lung volumes | |||||
| RV, % predicted | 98.2 ± 38.6 | 117.8 ± 61.8 | 104.2 ± 31 | 87.7 ± 24 | 0.13 |
| TLC, % predicted | 91.5 ± 16.3 | 96.4 ± 11.1 | 99.4 ± 16.7 | 86.3 ± 16.4 | 0.03 |
| RV/TLC, % predicted | 101.6 ± 34.1 | 119.2 ± 59.2 | 101.1 ± 22.8 | 94.5 ± 19.6 | 0.60 |
| Diffusing capacity | |||||
| DLCO, % predicted | 84.2 ± 14.5 | 89.5 ± 15.9 | 86 ± 15.1 | 81.1 ± 17.0 | 0.28 |
| CXR | |||||
| Not performed | 19 (9.2) | 8 (9.3) | 9 (18.3) | 2 (2.7) | < 0.001 |
| Normal | 130 (62.8) | 68 (79) | 32 (65.3) | 30 (41.1) | |
| Abnormal | 58 (28) | 10 (11.7) | 8 (16.3) | 41 (56.2) | |
| CT scan | |||||
| Not performed | 141 (67.8) | 74 (86) | 35 (71.4) | 32 (43.8) | 0.26 |
| Normal | 28 (13.5) | 6 (7) | 8 (16.3) | 14 (19.2) | |
| Abnormal | 39 (18.8) | 6 (7) | 6 (12.2) | 27 (37) | |
| Abnormal CT findings | 39 (18.8) | 6 (7) | 6 (12.2) | 27 (37) | < 0.001 |
Pulmonary symptoms include dyspnea, cough, chest pain, and exercise intolerance; SGRQ Saint George Respiratory Questionnaire, SaO2 Oxygen saturation at room air, FEV1 Forced expiratory volume at 1 s, FVC Forced vital capacity, RV Residual volume, TLC Total lung capacity, DLCO diffusion capacity for carbon monoxide, CXR chest X-ray, CT computerized tomography
*p < 0.05